<DOC>
	<DOCNO>NCT00226200</DOCNO>
	<brief_summary>This study involve FDA approve drug , Omalizumab , use treatment moderate severe allergic asthma control standard treatment . It work IgE control allergic reaction . We look effect non-allergic asthma . We hope prove Omalizumab effect non-allergic asthmatic allergic asthmatic .</brief_summary>
	<brief_title>Soluble CD23 Expression Asthma Patients Treated With OMA</brief_title>
	<detailed_description>This 1 year placebo control study look moderate severe asthmatic ( allergic non-allergic ) control medication . Skin test do determine allergic status , well base line IgE do . The Omalizumab administer injection base weight IgE level , ( twice month ) . At several time year pulmonary function test do , well blood drawn immunological assay ( CD23 FcER1 expression , TH1/TH2 cytokine , CD23 production ) . A battery questionnaires also determine quality life ( asthma ) , psychological stress measure parameter clinical response .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Moderate severe asthmatic ( base 1997 NHLBI guideline ) , control medication least 6 month , initial IgE level 30 700 IU , weigh 30 150 kg , otherwise healthy . Smoker , uncontrolled asthma , immunotherapy past six week , disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Allergic</keyword>
	<keyword>Non allergic</keyword>
</DOC>